Reboxetine

CHEMBL14370 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

313.4 g/mol

LogP

3.0

Phase

4

A selective norepinephrine reuptake inhibitor used outside the United States to treat major depressive disorder by increasing norepinephrine levels in the brain. It differs from most antidepressants by having minimal effect on serotonin reuptake.

Masse moléculaire

313,4000 g/mol

LogP

3,00

TPSA

39,70 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pain Management Schizophrenia Generalized Anxiety Disorder Stroke Obesity Major Depressive Disorder Chronic Pain

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOc1ccccc1OC(c1ccccc1)C1CNCCO1

InChI

InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3

Molecular Formula

C19H23NO3

HBD / HBA

1 / 4

Liaisons Rotatives

6

Atomes Lourds

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A selective norepinephrine reuptake inhibitor used outside the United States to treat major depressive disorder by increasing norepinephrine levels in the brain. It differs from most antidepressants by having minimal effect on serotonin reuptake.

Yes, Reboxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL14370. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 127151. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Reboxetine sur PillFYI

Structure

Données Clés

Formule: C19H23NO3

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.